FDA Opens Early Path for Home Medical Devices

Developers of home-use devices, including wearable monitors and infant sleep products, can now seek early FDA design feedback.

Updated on Nov. 3, 2026 in Healthcare

Isometric editorial illustration of a plain white wearable sensor patch beside a soft cushion form on a pale surface, with a faint ring of light suggesting a path from home to clinic. — The FDA selected initial participants for its READI-Home program, which gives home-use medical device developers early design feedback to reduce avoidable hospital readmissions. AI Illustration. Upload story photo >

Live Poll

Would you trust a home medical device to monitor your health after a hospital stay?

The FDA has selected initial participants for its READI-Home Innovation Challenge, a program aimed at reducing hospital readmissions through home-use medical devices. Selected devices include a wireless EEG monitoring system and a vibrational infant crib mattress, and three devices advance to an interaction phase with the agency for early engagement on design and testing.

Why it matters

The program aims to speed patient access to home-use medical devices after an acute hospital stay, addressing the logistical and financial burden of avoidable readmissions. For healthcare device makers and home health providers, it signals a federal channel for shaping home-use indications before full market entry.

Three devices were advanced to the FDA interaction phase from the initial selections. The Epitel REMI wearable EEG is applied to individuals six years and older for home and ambulatory use.

The players

U.S. Food and Drug Administration (FDA)

The federal agency that regulates medical devices sold in the United States, operating the READI-Home program.

Epitel

A neurotechnology company whose REMI Neuro Monitoring Home Health Hub is a wireless wearable EEG system for home use.

Current Health Limited

A developer of AI-based software medical devices, including the CRS Solution.

Skribe Medical

A medical device company whose Aurora System is a wearable multi-sensor adhesive patch.

The details

Selected devices span monitoring and therapy: Epitel's REMI Neuro Monitoring Home Health Hub is a wireless wearable EEG system for extended-duration monitoring applied at hospital discharge, while the Prapela Therapeutic Vibrational Crib Mattress embeds a miniaturized actuator that delivers low-amplitude vibration during infant sleep. The FDA selected the BD Self-Collection Kit, the CRS Solution from Current Health Limited, and the Aurora System from Skribe Medical to advance to the interaction phase. That phase gives developers early engagement with the agency and rapid feedback on device design and testing for home-use indications.

Article on the initial participant selections published November 3, 2026.

Market Landscape

The READI-Home Innovation Challenge places home-use medical devices into an FDA early-engagement channel rather than the standard submission track. Developers in home monitoring and therapy categories now have a named federal pathway to shape indications before broader commercialization.

Device makers in home monitoring and therapy should evaluate whether the READI-Home interaction phase fits their regulatory timeline. Healthcare providers planning post-discharge care may watch which home-use devices advance, since the program targets readmission reduction.

The takeaway

Companies developing home-use medical devices should assess whether early FDA engagement through the interaction phase suits their pipeline and documentation planning. Developers should consult qualified regulatory counsel before relying on the program for submission strategy.